Celltrion to adopt aggressive pricing for Avastin biosimilar | The Korea Herald

[THE INVESTOR] Korea’s biopharmaceutical firm Celltrion seeks to launch its version of Roche’s blockbuster cancer therapy Avastin at a highly competitive price to compete with other biosimilar makers making much faster progress.

Celltrion, which was the first to enter European markets with its biosimilars of Remicade and Rituxan, plans to implement a deep-discount pricing strategy for its version of Avastin called CT-P16.

Read complete article here:

Celltrion to adopt aggressive pricing for Avastin biosimilar.